234 related articles for article (PubMed ID: 22814307)
1. Predictive value of marker half-life in relapsed and nonrelapsed nonseminomatous germ cell testicular tumor patients undergoing chemotherapy.
Keskin S; Ekenel M; Başaran M; Bavbek S
Am J Clin Oncol; 2012 Aug; 35(4):369-72. PubMed ID: 22814307
[TBL] [Abstract][Full Text] [Related]
2. Does serum tumor marker half-life complement pretreatment risk stratification in metastatic nonseminomatous germ cell tumors?
Gerl A; Lamerz R; Clemm C; Mann K; Hartenstein R; Wilmanns W
Clin Cancer Res; 1996 Sep; 2(9):1565-70. PubMed ID: 9816334
[TBL] [Abstract][Full Text] [Related]
3. [Germ cell testicular tumors: understanding the kinetics of serum alpha-fetoprotein (AFP) during chemotherapy].
Riedinger JM; Eche N; Chevreau C; Fargeot P
Ann Biol Clin (Paris); 2008; 66(5):523-30. PubMed ID: 18957341
[TBL] [Abstract][Full Text] [Related]
4. [Efficacy of modified retroperitoneal lymph node dissection for testicular nonseminomatous germ cell tumors].
Liu ZW; Zhou FJ; Han H; Qin ZK; Yu SL; Li YH; Ye YL; Teng XY
Ai Zheng; 2008 Dec; 27(12):1302-6. PubMed ID: 19079998
[TBL] [Abstract][Full Text] [Related]
5. Paclitaxel+BEP (T-BEP) regimen as induction chemotherapy in poor prognosis patients with nonseminomatous germ cell tumors: a phase II study.
Tryakin A; Fedyanin M; Kanagavel D; Fainstein I; Sergeev J; Polockij B; Matveev V; Zakharova T; Garin A; Tjulandin S
Urology; 2011 Sep; 78(3):620-5. PubMed ID: 21764427
[TBL] [Abstract][Full Text] [Related]
6. Prognostic analysis of Japanese men with metastatic germ cell tumors showing favorable response to bleomycin, etoposide and cisplatin as first-line chemotherapy.
Kumano M; Miyake H; Hara I; Muramaki M; Takenaka A; Fujisawa M
Hinyokika Kiyo; 2007 Dec; 53(12):851-6. PubMed ID: 18203521
[TBL] [Abstract][Full Text] [Related]
7. Randomized trial comparing bleomycin/etoposide/cisplatin with alternating cisplatin/cyclophosphamide/doxorubicin and vinblastine/bleomycin regimens of chemotherapy for patients with intermediate- and poor-risk metastatic nonseminomatous germ cell tumors: Genito-Urinary Group of the French Federation of Cancer Centers Trial T93MP.
Culine S; Kramar A; Théodore C; Geoffrois L; Chevreau C; Biron P; Nguyen BB; Héron JF; Kerbrat P; Caty A; Delva R; Fargeot P; Fizazi K; Bouzy J; Droz JP;
J Clin Oncol; 2008 Jan; 26(3):421-7. PubMed ID: 18202419
[TBL] [Abstract][Full Text] [Related]
8. Surgery in infants and children with testicular and paratesticular tumours: a single centre experience over a 25-year-period.
Tröbs RB; Krauss M; Geyer C; Tannapfel A; Körholz D; Hirsch W
Klin Padiatr; 2007; 219(3):146-51. PubMed ID: 17525908
[TBL] [Abstract][Full Text] [Related]
9. Long-term followup results of 1 cycle of adjuvant bleomycin, etoposide and cisplatin chemotherapy for high risk clinical stage I nonseminomatous germ cell tumors of the testis.
Westermann DH; Schefer H; Thalmann GN; Karamitopoulou-Diamantis E; Fey MF; Studer UE
J Urol; 2008 Jan; 179(1):163-6. PubMed ID: 18001800
[TBL] [Abstract][Full Text] [Related]
10. Randomized phase III trial comparing retroperitoneal lymph node dissection with one course of bleomycin and etoposide plus cisplatin chemotherapy in the adjuvant treatment of clinical stage I Nonseminomatous testicular germ cell tumors: AUO trial AH 01/94 by the German Testicular Cancer Study Group.
Albers P; Siener R; Krege S; Schmelz HU; Dieckmann KP; Heidenreich A; Kwasny P; Pechoel M; Lehmann J; Kliesch S; Köhrmann KU; Fimmers R; Weissbach L; Loy V; Wittekind C; Hartmann M;
J Clin Oncol; 2008 Jun; 26(18):2966-72. PubMed ID: 18458040
[TBL] [Abstract][Full Text] [Related]
11. [Germ cell testicular tumors: understanding the kinetics of serum human chorionic gonadotropin during chemotherapy].
Riedinger JM; Eche N; Fargeot P
Ann Biol Clin (Paris); 2008; 66(5):515-21. PubMed ID: 18957340
[TBL] [Abstract][Full Text] [Related]
12. Dose-reduced first cycle of chemotherapy for prevention of life-threatening acute complications in nonseminomatous germ cell tumor patients with ultra high tumor markers and/or poor performance status.
Tryakin A; Fedyanin M; Bulanov A; Kashia S; Kurmukov I; Matveev V; Fainstein I; Gordeeva O; Zakharova T; Tjulandin S
J Cancer Res Clin Oncol; 2018 Sep; 144(9):1817-1823. PubMed ID: 29974210
[TBL] [Abstract][Full Text] [Related]
13. Treatment of favorable-prognosis nonseminomatous testicular germ cell tumors with etoposide, cisplatin, and reduced dose of bleomycin.
Brada M; Horwich A; Peckham MJ
Cancer Treat Rep; 1987 Jun; 71(6):655-6. PubMed ID: 2438041
[TBL] [Abstract][Full Text] [Related]
14. Prognostic significance of early serum tumor marker half-life in metastatic testicular teratoma.
Stevens MJ; Norman AR; Dearnaley DP; Horwich A
J Clin Oncol; 1995 Jan; 13(1):87-92. PubMed ID: 7528272
[TBL] [Abstract][Full Text] [Related]
15. Treatment outcome of metastatic testicular cancer at a single institution in Japan, a country with low incidence of germ cell tumor.
Kawai K; Hinotsu S; Oikawa T; Sekido N; Hattori K; Miyanaga N; Hasegawa Y; Kojima H; Shimazui T; Akaza H
Jpn J Clin Oncol; 2006 Nov; 36(11):723-30. PubMed ID: 17082218
[TBL] [Abstract][Full Text] [Related]
16. Significance of elevated preoperative alpha-fetoprotein in postchemotherapy residual tumor resection for the disseminated germ cell tumors.
Kobayashi T; Kawakita M; Terachi T; Habuchi T; Ogawa O; Kamoto T
J Surg Oncol; 2006 Dec; 94(7):619-23. PubMed ID: 17111392
[TBL] [Abstract][Full Text] [Related]
17. Is serum tumor marker half-life a guide to prognosis in metastatic nonseminomatous germ cell tumors?
Gerl A; Lamerz R; Mann K; Clemm C; Wilmanns W
Anticancer Res; 1997; 17(4B):3047-9. PubMed ID: 9329598
[TBL] [Abstract][Full Text] [Related]
18. Prognostic factors in metastatic nonseminomatous germ cell tumours.
Hanson PR; Belitsky P; Millard OH; Lannon SG
Can J Surg; 1993 Dec; 36(6):537-40. PubMed ID: 7504978
[TBL] [Abstract][Full Text] [Related]
19. Serum tumor marker half-life during chemotherapy allows early prediction of complete response and survival in nonseminomatous germ cell tumors.
Toner GC; Geller NL; Tan C; Nisselbaum J; Bosl GJ
Cancer Res; 1990 Sep; 50(18):5904-10. PubMed ID: 1697503
[TBL] [Abstract][Full Text] [Related]
20. Identification of a subgroup with worse prognosis among patients with poor-risk testicular germ cell tumor.
Kojima T; Kawai K; Tsuchiya K; Abe T; Shinohara N; Tanaka T; Masumori N; Yamada S; Arai Y; Narita S; Tsuchiya N; Habuchi T; Nishiyama H
Int J Urol; 2015 Oct; 22(10):923-7. PubMed ID: 26094715
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
